Allianz Asset Management
PDLI

Allianz Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Allianz Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-16,168
Closed -$46K – 2648
2020
Q1 		$46K Sell
16,168
-22,124
-58% -$71.3K ﹤0.01% 2427
2019
Q4 		$125K Sell
38,292
-353
-0.9% -$1.02K ﹤0.01% 2711
2019
Q3 		$83K Sell
38,645
-80,796
-68% -$216K ﹤0.01% 2693
2019
Q2 		$375K Sell
119,441
-17,840
-13% -$57.9K ﹤0.01% 2439
2019
Q1 		$511K Sell
137,281
-217,366
-61% -$734K ﹤0.01% 2317
2018
Q4 		$1.03M Sell
354,647
-14,328
-4% -$39.4K ﹤0.01% 2022
2018
Q3 		$970K Sell
368,975
-195,059
-35% -$479K ﹤0.01% 2234
2018
Q2 		$1.32M Sell
564,034
-370,051
-40% -$1.03M ﹤0.01% 2119
2018
Q1 		$2.75M Sell
934,085
-28,183
-3% -$76.9K ﹤0.01% 1783
2017
Q4 		$2.64M Buy
962,268
+21,180
+2% +$65.1K ﹤0.01% 1912
2017
Q3 		$3.19M Buy
941,088
+146,817
+18% +$408K ﹤0.01% 1836
2017
Q2 		$1.98M Sell
794,271
-24,792
-3% -$57K ﹤0.01% 1985
2017
Q1 		$1.86M Sell
819,063
-57,413
-7% -$127K ﹤0.01% 2025
2016
Q4 		$1.86M Buy
876,476
+394,938
+82% +$1.1M ﹤0.01% 2001
2016
Q3 		$1.58M Buy
481,538
+110,369
+30% +$350K ﹤0.01% 2076
2016
Q2 		$1.17M Buy
371,169
+39,455
+12% +$132K ﹤0.01% 2134
2016
Q1 		$1.1M Buy
331,714
+150,479
+83% +$469K ﹤0.01% 2036
2015
Q4 		$642K Sell
181,235
-15,460
-8% -$64.7K ﹤0.01% 2128
2015
Q3 		$990K Sell
196,695
-475,617
-71% -$2.73M ﹤0.01% 1839
2015
Q2 		$4.32M Sell
672,312
-881,338
-57% -$5.9M ﹤0.01% 1428
2015
Q1 		$10.9M Sell
1,553,650
-963,150
-38% -$6.98M 0.01% 920
2014
Q4 		$19.4M Buy
2,516,800
+998,239
+66% +$7.9M 0.02% 725
2014
Q3 		$11.3M Buy
1,518,561
+88,635
+6% +$823K 0.01% 791
2014
Q2 		$13.8M Buy
1,429,926
+776,415
+119% +$6.92M 0.02% 665
2014
Q1 		$5.43M Sell
653,511
-53,039
-8% -$455K 0.01% 934
2013
Q4 		$5.96M Buy
706,550
+138,403
+24% +$1.17M 0.01% 896
2013
Q3 		$4.53M Buy
568,147
+118,920
+26% +$956K 0.01% 951
2013
Q2 		$3.47M Buy
+449,227
New +$3.5M ﹤0.01% 1021

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
ECM
Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Allianz Asset Management's PDLI Position: Q2 2020 in Review

Allianz Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q2 2020, closing a stake of 16,168 shares — an estimated $46K sold.

Allianz Asset Management first reported a position in PDLI in Q2 2013 and held it in 28 quarters. The position peaked at $19.4M in Q4 2014. 136 funds tracked by Wall St. Rank hold PDLI as of Q2 2020.

  • Allianz Asset Management reported no remaining PDL BioPharma, Inc. position as of Q2 2020 after selling out during the quarter.
  • Allianz Asset Management sold 16,168 PDL BioPharma, Inc. shares in Q2 2020, an estimated $46K.
  • Allianz Asset Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 28 quarters.
  • Allianz Asset Management's PDL BioPharma, Inc. position peaked at $19.4M in Q4 2014.
  • 136 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2020.

Based on Allianz Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.